Bladder Cancer Clinical Trials

- This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme ...

A research study is evaluating an investigational treatment for renal cell carcinoma (RCC). This research study may be an option if you: Are at least 18 years of age Have a confirmed diagnosis of RCC Have had a recent nephrectomy procedure Other criteria apply. Please make sure to discuss with ...

This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially ...

This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or lymph nodes or has spread to other places in the body. Sorafenib tosylate may stop ...

This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment. Approximately 560 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to regorafenib or placebo (1/3 chance to receive placebo). Primary endpoint of ...

A Humanitarian Use Device trial for patients who have hepatocellular carcinoma of the liver.

To evaluate the pharmacokinetics and safety of copanlisib in subjects with impaired hepatic or renal function in comparison to healthy subjects

People with urothelial (urinary system) or bladder cancer are asked to participate in a research study being conducted by the North Shore University Hospital. Patient Inclusion Criteria = You may be eligible to participate in this study if you: Are at least 18 years of age Have been diagnosed with ...

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00980460?term=AHEP0731&rank=1

Patients with newly diagnosed or recurrent high risk non-muscle invasive bladder cancer who have undergone transurethral resection of bladder tumor (TURBT) and received 3-6 instillations of intravesical treatment with BCG induction therapy will be enrolled in this two stage study.